Monte Rosa's MRT-8102, an oral molecular glue degrader that removes NEK7 to block NLRP3 inflammasome assembly, reduced NEK7 by 80–90% and lowered hsCRP by a median of 85%, IL-6 by 54%, fibrinogen by 28% and lipoprotein(a) by 24% in 108 adults with obesity and elevated cardiovascular risk over four weeks. Downstream plaque-associated damage signals including calprotectin, S100A12 and SAA fell by roughly half, with no increase in infections and adverse event rates comparable to placebo. The data are company-reported, biomarker-based and not yet linked to clinical outcomes.
Key Points
- NEK7 degradation lowered hsCRP 85%, IL-6 54% in four weeks
- Lipoprotein(a) fell 24% without raising LDL or triglycerides
- NLRP3 risk-allele carriers started with highest inflammatory burden
Longevity Analysis
Chronic inflammasome activation links arterial disease to a broader pattern of low-grade immune signalling that accelerates tissue decline, and removing the protein required to assemble the alarm — rather than neutralising one cytokine downstream — targets the source of the signal. Lipoprotein(a) movement without adverse lipid shifts, alongside unchanged infection rates, suggests the defensive response can be quieted selectively rather than suppressed wholesale. The genotype finding is the most actionable detail for clinicians: a third of participants carried risk alleles and entered the trial with higher damage markers, pointing toward inflammatory profiling before intervention rather than after.
Original published by Longevity.Technology, by Kyle Umipig.